Antipsychotics in Pregnancy — MRCPsych Paper B MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Continue aripiprazole after shared risk–benefit discussion, with perinatal input, weight monitoring and gestational-diabetes screening including an oral glucose tolerance test
Explanation lettering: E = shown as A · A = shown as E
B is correct. NICE advises that a pregnant woman who is stable on an antipsychotic and likely to relapse without it should continue the antipsychotic. Her two rapid, severe relapses after previous discontinuation make relapse risk the decisive feature. Management should include an individualised discussion of maternal, fetal and neonatal risks, preferably with specialist perinatal input, while avoiding unnecessary switching or polypharmacy. NICE also recommends monitoring for excessive weight gain and gestational diabetes and offering an oral glucose tolerance test. A exposes her to a substantial and predictable relapse risk. C is inappropriate because greater exposure data alone do not justify switching an effective treatment, which may destabilise her. D substitutes a drug that is not a routine treatment for schizophrenia and has its own pregnancy risks. E omits NICE-recommended diabetes screening.
Reference: National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance (CG192), recommendations 1.4.20–1.4.25, 2014, current guideline. https://www.nice.org.uk/guidance/cg192/chapter/Recommendations